Purchase this article with an account.
Lindsay Adam, James Massengill, Colleen Cebulla, Mohamed Abdel-Rahman; Cyclooxygenase-2 (COX-2) expression in primary uveal melanoma and the potential role for adjuvant treatment with COX-2 inhibitors. Invest. Ophthalmol. Vis. Sci. 2013;54(15):4212.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Cyclooxygenase-2 (COX-2) has previously been shown to have an influential role in tumorigenesis in a variety of malignancies. The objective of this study was to examine COX-2 expression and function in primary uveal melanoma and uveal melanoma cell lines and to evaluate correlation with histological, genetic, and clinical markers.
The expression of COX-2 was assessed by immunohistochemistry. The cytotoxicity of COX-2 inhibitor Celecoxib was assessed on five uveal melanoma cell lines (C918, OCM3, MEL270, MEL202, 92.1) using in-vitro cell proliferation assay.
Using immunohistochemistry, 4 of the 15 specimens (26.7%) showed intense staining for COX-2. No statistically significant associations (p <0.05) were identified between COX-2 expression and survival, cell type, tumor size, tumor genetics, pattern distribution, or tumor invasion. The IC50 ranged from 11.4 to 29.3 microMolar in the tested cell lines.
Increased COX-2 expression does not appear to be strongly correlated with poor prognostic indicators in primary uveal melanoma. COX-2 could be a potential adjuvant therapy in a small subset of patients.
This PDF is available to Subscribers Only